Citryll Doses First Patient in Phase IIa Hidradenitis Suppurativa Trial for CIT-013
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 2 day ago0mins
- Trial Initiation: Citryll has commenced its Phase IIa clinical trial for CIT-013 targeting moderate to severe hidradenitis suppurativa in Oss, Netherlands, with the first patient dosed, marking a significant advancement in treating immune-mediated inflammatory diseases.
- Patient Cohort Size: The trial will enroll 96 participants over a 12-week period to assess the efficacy, safety, and tolerability of CIT-013, addressing a critical gap in treatment options currently available for this condition.
- Advisory Board Formation: Citryll has established a Clinical Advisory Board comprising global dermatology experts to provide strategic guidance throughout the trial, enhancing the company’s credibility and expertise in the field.
- Innovative Treatment Mechanism: As the first monoclonal antibody targeting extracellular traps, CIT-013 features a unique dual mechanism of action that may offer more effective treatment options for hidradenitis suppurativa and other inflammatory diseases, positioning the company for long-term growth in the biopharmaceutical sector.
CITR.A
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CITR
Wall Street analysts forecast CITR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CITR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 7.700
Low
Averages
High
Current: 7.700
Low
Averages
High
No Data
About CITR
General Enterprise Ventures, Inc. is a flame retardant and flame suppression company for the residential home industry. The Company's products include MFB31- CitroTech, which is utilized in wildfire defense, and MFB34-CitroTech, which is used to treat lumber to inhibit fire and mold. It is developing a coating to treat lumber during manufacture prior to distribution. The Company holds various intellectual property in the form of patents and trademarks in the fields of fire suppression, mapping and tracking of fire-retardant dispersion and fire inhibition chemistry and technology. Its products are used in the residential home industry, including individual homeowners, developers and other third parties. The Company installs systems to deploy its product remotely to provide a buffer zone around properties to prevent combustion.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the primary goal of Citryll’s Phase IIa clinical trial?
How does CIT-013 address the treatment gap for hidradenitis suppurativa?
What are the chances of CIT-013 succeeding in Phase IIa trials?
How might the trial results impact Citryll’s future in the biopharmaceutical sector?